Phase I/II Study of Combination Therapy With MRA (Tocilizumab) and Gemcitabine for Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220858

Enrollment

Registered

2009-09-14

Start date

2009-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable locally advanced or metastatic pancreatic cancer

Interventions

investigational material(s) Generic name etc : MRA INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 8

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Histologically or cytologically confirmed pancreatic cancer with unresectable locally advanced or metastatic disease -No prior chemotherapy or radiotherapy for pancreatic cancer, other than resection -C-reactive protein(CRP) >= 2.0 mg/dL -At least one measurable target lesion by RECIST ver 1.0 -ECOG performance status of 0 - 2

Exclusion criteria

Exclusion criteria: -Patients who have an infection that requires systemic administration of drugs such as antibiotics, antiviral drugs or antifungal drugs. -Patients has non-neoplastic disease requiring systemic administration of corticosteroids. -Women who are pregnant or nursing mothers. -The patient have a pulmonary disorder such as idiopathic pulmonary fibrosis or interstitial pneumonia or has a history of these. -Patients who undergone biliary stent insertion or cholangiojejunostomy.

Design outcomes

Primary

Measure	Time frame
Efficacy, Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026